17 July 2017 - The EMA has published a draft agenda for this week's CHMP meeting.

The CHMP is due to issue initial opinions for the following technologies:

• Avelumab
  
• Dupulimab
• Entecavir monohydrate
  
• Iloperidone
  
• Lacosamide
  
• Lutetium (Lu 177) oxodotreotide
  
• Etirinotecan pegol
  
• Midostaurin
  
• Darunavir ethanolate with cobicistat and emtricitabine and tenofovir alafenamide fumarate
  
• Atezolizumab
  
• Cyclosporin
  
• Telotristat ethyl
  

Read CHMP agenda